ArticleHealth economics review2025
Cost-effectiveness of the addition of sintilimab as a first-line therapy for locally advanced or metastatic oesophageal squamous cell carcinoma: a Chinese healthcare system perspective.
Cuicui Yu et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.